GOSS Stock Forecast & Price Target

Gossamer Bio Inc. has reported notable clinical advancements with its product seralutinib, showcasing a statistically significant improvement in six-minute walk distance (6MWD) of +28.2 meters from baseline, compared to +13.5 meters for the placebo, indicating a clinically meaningful effect that is expected to continue beyond the initial evaluation period. The company’s management highlighted high confidence in its execution as it approaches a pivotal year, particularly with seralutinib showing sustained improvement across multiple metrics, including pulmonary vascular resistance and biomarkers, unlike other PAH therapies that tend to plateau. Furthermore, subgroup analyses in functional class III patients indicated potential for over 30-meter improvements, reinforcing the promising outlook for seralutinib as a transformative treatment option in pulmonary arterial hypertension.

Gossamer Bio Inc has significantly revised its fiscal year 2032 revenue estimate down to $324 million from the previous $993 million, indicating a concerning trend in revenue projections. The clinical trial results for PROSERA did not meet expectations, raising doubts about the viability of a registrational path for its lead drug candidate, seralutinib, which may impede market traction. Additionally, the increase in the discount rate to 40% reflects heightened risk perceptions and has consequently reduced the company’s target valuation to approximately $1 per share.